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NGOING DEBATES IN THE PHARMACEUTICAL 
sector about intellectual property,1,2 pricing 
and reimbursement,3,4 and public research 
investments5 have a common denominator: the pur-
suit of innovation. However, there is little clarity about 
what constitutes a true pharmaceutical innovation, 
and as a result there is confusion about what kind of 
new products should be pursued, protected and en-
couraged through health policy and clinical practice.6 
If the concept of pharmaceutical innovation can be 
clarified, then it may become easier for health policy-
makers and practitioners to evaluate, adopt and pro-
cure products in ways that appropriately recognize, 
encourage and give priority to truly valuable pharma-
ceutical innovations.  
 To describe a product as innovative implies that it 
has properties that are worthy of recognition and re-
ward. The term suggests that the product has unique 
value. However, notions of value are a matter of per-
spective. Commercial value, for example, is generally 
assessed from the perspective of a firm’s profitability. 
The perceived societal value of ordinary goods is often 
defined by consumer preferences as reflected by their 
willingness to pay for products that they perceive to be 
“good value for money.” However, pharmaceuticals 
are not ordinary goods. 
 Pharmaceutical products have no intrinsic value to 
patients or to society; rather, their value lies in the 
health outcomes they generate. Pharmaceuticals are 
licensed for sale on the basis of whether they safely 
and efficaciously address a health care need, not be-
cause patients might have preferences concerning 
their shape, colour, taste or brand. Although charac-
teristics like shape, colour, taste or brand may play a 
role in improving health outcomes — perhaps by in-
creasing treatment adherence — it is the measurable 
improvements in health outcomes that generate 
value for society. Product characteristics are analo-
gous to surrogate endpoints in clinical trials insofar 
as they are of societal value only to the extent that 
they predict clinical or “hard” endpoints.7,8 
 Although the concepts of novelty and innovation 
are often associated with one another,9 defining the 
societal value of pharmaceuticals exclusively in terms 
of the production of health outcomes implies that 
product novelty alone does not constitute pharma-
ceutical innovation. New chemical structures or 
mechanisms of action do not necessarily generate 
improved health outcomes:10,11 a new pharmaceutical 
product must also have some degree of effectiveness 
(net of treatment risks).6 It should be noted that ef-
fectiveness alone is not enough to qualify a new 
product as an innovation. A generic drug, for exam-
ple, may safely and efficaciously address a health 
care need — and may provide value to patients and 
society — but it would hardly be considered an inno-
vation. Thus, neither novelty nor effectiveness alone 
is enough to qualify as pharmaceutical innovation. 
Even the combination of novelty and effectiveness is 
not enough. 
 Pharmaceutical innovation requires novelty of effec-
tiveness. Pharmaceutical innovations create value to 
society by making it possible to generate improvements 
in patient health (net of treatment risks) that were pre-
viously unattainable. It is the uniqueness of such health 
improvements that defines pharmaceutical innova-
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tions. A drug can be considered a pharmaceutical inno-
vation only if it meets otherwise unmet or inadequately 
met health care needs. This will depend on its efficacy, 
safety and convenience of use relative to the technolo-
gies available when it is introduced. For example, 
cimetidine, the prototypical histamine-2 receptor an-
tagonist, was considered a pharmaceutical innovation 
when it was introduced in 1977 because it safely and ef-
fectively addressed a previously inadequately met 
need.12 However, the notion of pharmaceutical innova-
tion is time-dependent. Competition and technological 
change mean that the standard by which the unique 
value of a pharmaceutical innovation is measured — 
the ability to address health care needs that are other-
wise not addressable — will change over time. Neither 
cimetidine nor other histamine-2 receptor antagonists 
would be considered innovations today because the 
outcomes they generate have been matched and even 
surpassed by other technologies. 
 Replicating outcomes obtainable with existing 
treatments is important for market competition but 
it does not represent innovation. However, surpass-
ing existing levels of performance in terms of 
established efficacy, safety or both would be consid-
ered pharmaceutical innovation. Again, consider 
advances in gastroenterology: the first proton pump 
inhibitor, omeprazole, was an innovation when it was 
introduced in 1989 because it met a given need more 
effectively than histamine-2 receptor antagonists. 
Proton pump inhibitors have since become the main-
stay of treatment for acid-related gastrointestinal 
disease in adults. Although they continue to generate 
valuable outcomes, they would no longer be consid-
ered innovations. 
 A pharmaceutical innovation may be thought of as 
incremental, substantial or radical according to the 
significance of the unmet health care need it ad-
dresses (gravity of unmet need) and the extent to 
which it improves net health outcomes related to that 
need (comparative effectiveness) (Figure 1). The 
gravity of an unmet need can be thought of as the gap 
between the health status that patients with a par-
ticular medical condition could attain with existing 
technologies and the health status they could expect 
if they did not have that medical condition. The low-
est gravity of unmet need (a value of zero) represents 
cases in which patients experience no deprivation in 
health status if they receive existing treatments or 
cases in which the nature of the condition is trivial in 
terms of health status (e.g., male pattern baldness). 
The highest gravity of unmet need (a value of 1) rep-
resents cases in which the condition has a prognosis 
of immediate death given existing treatment options. 
 Gravity of unmet need establishes the potential 
for pharmaceutical innovation (i.e., the maximum 
improvement in health status that a new drug might 
offer, over and above existing technologies). For a 
condition with a low gravity of unmet need, such as 
colour blindness, there is a limited potential for 
pharmaceutical innovation. To determine the level 
of pharmaceutical innovation that a drug actually 
achieves, one must also examine its comparative ef-
fectiveness in terms of net improvements in health 
outcomes, taking into account the negative effects of 
the drug (e.g., side effects and adverse events). 
Drugs with zero comparative effectiveness offer no 
improvement in health outcomes compared with ex-
isting treatments. The highest possible comparative 
effectiveness (a value of 1) indicates the ideal (and 
seldom, if ever, realized) situation in which a drug is 
perfectly safe and entirely closes the gap between 
the health status attainable with prevailing treat-
ments and the ideal health status for the treated 
population. The categories of innovation in Figure 1 
are drawn with a lower border because a medicine 
must offer some level of comparative health benefit 
to be considered an innovation, no matter how 
grave the condition it aims to remedy. 
 The greater the gravity of the unmet need ad-
dressed by a new treatment, or the greater its 
comparative effectiveness in addressing that need, 
the greater the degree of pharmaceutical innovation. 
Radical innovations, or “breakthroughs,” are moder-
ately to highly effective treatments for conditions 
that would otherwise significantly reduce the quality 
or length of life or both, or treatments that provide a 
near-total cure in cases in which the prevailing un-
met needs are more moderate. Substantial 
innovations offer fair to modest improvements in 
health outcomes for patients with grave unmet 
needs, or substantial improvements over existing 
treatments for patients whose unmet health care 
needs are less serious. Finally, incremental innova-
tions offer minor to moderate improvements over 
existing treatments for patients whose unmet needs 
are moderate to trivial. 
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 Breakthrough drugs (or radical pharmaceutical 
innovations) generate the most significant societal 
value through their unique ability to generate im-
provements in health outcomes not otherwise 
possible. To qualify as a breakthrough, a new drug 
must offer significant improvements over existing 
treatments, even when the prevailing unmet needs 
are dire. For example, a drug that briefly extends 
the life expectancy of terminally ill patients might 
be considered an innovation, but to be considered a 
breakthrough it would have to provide these pa-
tients with a quantity and quality of life close to 
what they could have expected in the absence of the 
underlying illness. For this reason, the break-
through category does not intersect with the lower 
horizontal line of Figure 1. 
 There is limited scope for pharmaceutical innova-
tion for conditions for which existing therapies offer 
relatively good outcomes. New treatments within a 
drug class may offer modest therapeutic gains in ef-
ficacy or safety, but being different does not in itself 
constitute innovation. For example, early and late 
entrants into a drug class might each be more effec-
tive or better tolerated among certain population 
subgroups. However, late entrants will not repre-
sent significant pharmaceutical innovation unless 
they are systematically superior to early ones. 
 The value of new drugs that produce outcomes 
similar to those achievable with other treatment op-
tions lies not in innovation but in the potential 
competition that these products may bring to the 
marketplace. Such competition may have value for 
consumers and for society more generally through 
reduced costs per outcome achieved. However, the 
cost of developing such medicines includes the sig-
nificant investment and the risks to participants in 
various stages of clinical trials, as well as the funds 
spent on marketing efforts to differentiate the new 
drug from existing treatments, and all of these costs 
divert resources from the pursuit of treatments to 
meet more substantial unmet health needs.1,13,14  
 Ultimately, it is commercial value that drives in-
vestments and activities in the private sector. Firms 
may strive for commercial performance by develop-
ing drugs that effectively address grave, unmet health 
care needs. Firms may also be commercially innova-
tive without generating pharmaceutical innovations, 
such as when they develop a marketing campaign 
that builds brand loyalty for a product that is compa-
rable to existing alternatives. Indeed, when Figure 1 
is viewed from a societal perspective on a global or 
national basis, it appears that most of the commer-
cial activity in the pharmaceutical market is focused 
on product development and related marketing ac-
tivities in therapeutic areas in which new products 
would at best provide incremental advances in popu-
lation health. That is, much of the innovation in this 
sector is commercial, not pharmaceutical. 
 The fact that commercial incentives are not al-
ways aligned with the production of major 
pharmaceutical innovations is evident not only in 
the global divide between burden of illness and drug 
research and development,15,16 but also in the share 
of product development, marketing and sales in 
wealthy countries that is accounted for by medicines 
that offer little or no advantage over established 
treatment alternatives.17 Between 1993 and 2004, 
only one-third of US applications for the licensing 
of new molecular entities were promising enough to 
qualify for priority review by the US Food and 
Drugs Administration.18 The proportion of new 
drugs that represent true breakthroughs is likely 
lower. Between 1981 and 2000, Prescrire Interna-
tional rated only 74 (3%) of nearly 2300 new drugs 
or new indications for existing drugs as major or 
important therapeutic gains.19 Fewer than 10% of 
recently developed biotechnology drugs and cancer 
treatments have been deemed to offer substantial 
Figure 1: A model of pharmacological innovation    
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improvements with respect to hard clinical end-
points.20,21 
 Ultimately, the pharmaceutical industry is not to 
blame. The industry’s focus on research and mar-
keting activities for products that do not 
dramatically advance attainable health outcomes 
results from the way drugs are appraised, selected 
and purchased by health practitioners, patients, 
policy-makers and insurers. If these actors placed a 
premium on true pharmaceutical innovation—
demonstrably safe and effective treatments for pre-
viously unmet needs—and encouraged competition 
among technologies that produce equivalent health 
outcomes, private investments in research and de-
velopment would be stimulated in the areas of 
greatest value to society.4  
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